Jump to main content
Jump to site search

Issue 1, 2019
Previous Article Next Article

Repurposing antitubercular agent isoniazid for treatment of prostate cancer

Author affiliations


The development of versatile antitumor agents with tumor-imaging, targeting and therapeutic activity is promising for clinical cancer therapy. Prostate cancer is still the one of the leading threats to males. Current therapies have restricted clinical efficiency for patients with advanced and metastatic prostate cancer. Recent studies demonstrate that monoamine oxidase A (MAOA) levels elevate with prostate cancer aggression and metastasis. In addition, MAOA inhibitor therapies have been reported as an effective means to reduce the metastasis of prostate cancer and extend mouse survival. Thus, these findings provide evidence that MAOA is promising for the treatment of metastatic and advanced prostate cancer. Herein, three isoniazid (INH)–dye conjugates were synthesized by conjugating MAOA inhibitor INH with mitochondria-targeting NIRF heptamethine dyes to improve the therapeutic efficacy of prostate cancer. These INH–dye conjugates could accumulate in PC-3 cellular mitochondria via organic anion transport peptide (OATP), increase ROS generation, and induce cancer cells apoptosis. In prostate cancer bearing xenografts, INH–dye conjugates showed significantly improved tumor-homing characteristics, resulting in potent antitumor activity via a reduction in MAOA activity. These results suggest that INH–dye conjugates have great potential to be used as versatile antitumor agents with prostate cancer targeting, NIR imaging, and potent antitumor efficacy.

Graphical abstract: Repurposing antitubercular agent isoniazid for treatment of prostate cancer

Back to tab navigation

Supplementary files

Publication details

The article was received on 26 Sep 2018, accepted on 09 Nov 2018 and first published on 12 Nov 2018

Article type: Paper
DOI: 10.1039/C8BM01189C
Citation: Biomater. Sci., 2019,7, 296-306

  •   Request permissions

    Repurposing antitubercular agent isoniazid for treatment of prostate cancer

    Q. Lv, D. Wang, Z. Yang, J. Yang, R. Zhang, X. Yang, M. Wang and Y. Wang, Biomater. Sci., 2019, 7, 296
    DOI: 10.1039/C8BM01189C

Search articles by author